- Home
- AKTX vs ITRM Comparison
AKTX vs ITRM Comparison
Compare AKTX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- ITRM
- Stock Information
- Founded
- AKTX N/A
- ITRM 2015
- Country
- AKTX United States
- ITRM Ireland
- Employees
- AKTX N/A
- ITRM N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- ITRM Health Care
- Exchange
- AKTX Nasdaq
- ITRM Nasdaq
- Market Cap
- AKTX 35.7M
- ITRM 40.0M
- IPO Year
- AKTX N/A
- ITRM 2018
- Fundamental
- Price
- AKTX $0.76
- ITRM $0.68
- Analyst Decision
- AKTX Strong Buy
- ITRM Strong Buy
- Analyst Count
- AKTX 2
- ITRM 1
- Target Price
- AKTX $3.30
- ITRM $9.00
- AVG Volume (30 Days)
- AKTX 91.6K
- ITRM 699.1K
- Earning Date
- AKTX 08-13-2025
- ITRM 11-13-2025
- Dividend Yield
- AKTX N/A
- ITRM N/A
- EPS Growth
- AKTX N/A
- ITRM N/A
- EPS
- AKTX N/A
- ITRM N/A
- Revenue
- AKTX N/A
- ITRM N/A
- Revenue This Year
- AKTX N/A
- ITRM N/A
- Revenue Next Year
- AKTX N/A
- ITRM $482.25
- P/E Ratio
- AKTX N/A
- ITRM N/A
- Revenue Growth
- AKTX N/A
- ITRM N/A
- 52 Week Low
- AKTX $0.57
- ITRM $0.61
- 52 Week High
- AKTX $3.85
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- AKTX 37.47
- ITRM 42.81
- Support Level
- AKTX $0.75
- ITRM $0.64
- Resistance Level
- AKTX $0.89
- ITRM $0.76
- Average True Range (ATR)
- AKTX 0.07
- ITRM 0.05
- MACD
- AKTX 0.01
- ITRM 0.01
- Stochastic Oscillator
- AKTX 57.86
- ITRM 47.85
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.